'Why we do What we do in Cardiology'22 Kesä 2024

Improving Left Ventricular Ejection Fraction in Heart Failure Patients: Insights from the HF-OPT Study

The HF-OPT study investigated the improvement of left ventricular ejection fraction (LVEF) beyond 90 days in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF).

In this prospective, multicenter observational study, 1,300 patients with HFrEF (LVEF ≤35%) were initially enrolled.

Participants wore a wearable cardioverter-defibrillator (WCD) and received guideline-directed medical therapies (GDMT).

LVEF was measured at 0, 90, 180, and 360 days.

By day 90, 46% had an LVEF >35%; this increased to 68% by day 180 and 77% by day 360.

High GDMT usage was noted, with 97% on beta-blockers, 94% on ACE inhibitors/angiotensin-receptor blockers/ARNI, and 62% on mineralocorticoid antagonists by day 180.

Achieving target doses of all three GDMT classes was associated with significant LVEF improvement.

The study recorded low rates of ventricular arrhythmias beyond the initial 90 days.

These results underscore the potential benefits of continuous GDMT optimization. They suggest that delayed implantable cardioverter-defibrillator (ICD) implantation may be reasonable for selected patients, allowing for further LVEF improvement.

This emphasizes the importance of optimal dosing and continuous GDMT for effective heart failure management, highlighting the need for expedited GDMT titration and a tailored approach to heart failure care.

Reference: European Heart Journal, ehae334, https://doi.org/10.1093/eurheartj/ehae334

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(35)

REDUCE-AMI Trial: Diminishing Role of Beta-Blockers in ACS with preserved LVEF

1. The REDUCE-AMI trial showed no significant benefit of beta-blockers in reducing all-cause mortality or future myocardial infarction in patients with acute myocardial infarction and preserved left v...

24 Kesä 20244min

AI in Cardiovascular Medicine: JACC Review

Overview: This review discusses the use and future directions of AI in cardiology, focusing on areas like electrocardiography, telemetry and wearables, echocardiography, CMR, nuclear cardiology, CT, e...

21 Kesä 20246min

2024 ACC Peripheral Artery Disease (PAD) Guidelines

Collaborative vascular care is emphasized to address health disparities, gaps in medical therapy, structured exercise, and good foot care along with appropriate revascularization to prevent limb loss....

31 Touko 20246min

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Mavacamten: Class 1 recommendation for symptomatic obstructive HCM. Exercise: Now allows for "vigorous" activity; competitive lev...

21 Touko 20249min

DOACs: When direct oral anticoagulants should not be used?

Key Points: Positive Aspects of DOACs: DOACs are acknowledged for their convenience, efficacy, and safety in conditions like atrial fibrillation (AF) and venous thromboembolism (VTE). The review sup...

29 Tammi 20244min

Cath: NPO vs Eating before Heart Cath

Background: Traditional practice requires fasting before cardiac catheterization, but there's no evidence to support it. Objective: This study compared a heart-healthy pre-procedure diet with fasting ...

26 Tammi 20243min

Stable CAD and Angina: PCI without medical therapy as first treatment (ORBITA-2)

Key Points In patients not taking antianginal meds, PCI alleviated some—but not all—symptoms Background: Percutaneous coronary intervention (PCI) is commonly used to alleviate stable angina symptom...

22 Tammi 20243min